FAQ on NanoViricides' Breakthrough Measles Drug Success
Summary
What is NV-387?
NV-387 is NanoViricides’ lead drug candidate, a broad-spectrum antiviral drug designed to treat Measles by mimicking human cell features to bind and neutralize viruses.
Why is NV-387’s success significant?
With global Measles cases surging and vaccine coverage declining, NV-387’s success in increasing survival rates in humanized animal studies without toxicity marks a potential first therapeutic option for Measles.
How does NV-387 work?
NV-387 mimics human cell features to bind and neutralize viruses, targeting over 90% of human pathogens, demonstrating dose-dependent efficacy in studies.
Who is involved in the development of NV-387?
NanoViricides, Inc., a clinical-stage developer of broad-spectrum antivirals, is advancing NV-387, with technology licensed from TheraCour Pharma, Inc.
What were the results of the NV-387 study?
In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%—from 7.4 to 17 days—with no observed toxicity.
When can NV-387 be available for human use?
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, but an exact date for filing an IND cannot be projected due to dependence on external collaborators.
Where can I find more information about NanoViricides and NV-387?
For more information, visit NanoViricides’ website at www.NanoViricides.com or view the latest news and updates at https://ibn.fm/NNVC.
What other diseases is NanoViricides targeting with its technology?
NanoViricides plans to develop NV-387 for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and is advancing NV-HHV-1 for Shingles treatment.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 111472